Identification of Agents that Inhibit the Generation and Neurotoxicity of Cross-linked B-amyloid Protein Species
Researchers:
Funding year(s):
2006 - 2007
Funding to date:
$200,000
We have coined the term CAPS to describe cross-linked-Beta-amyloid protein species. CAPS, particularly dimeric forms, are highly neurotoxic. CAPS are also abundant in vivo with dimeric species alone comprising as much as 40% of the total A-beta pool in late state AD brain. In this study we plan to screen compound libraries for potential therapeutic agents that attenuate the levels and/or cytotoxic activity of CAPS.
